BMS-986142

Name: BMS-986142 | 1643368-58-4
Brand: US-CATO
SKU: S57C1359447_5_MG
Price: 19998.0 USD
Availability: OutOfStock

Cat. No S57C1359447_5_MG

Vendor: US-CATO

Product Information

Product Name

BMS-986142

Brand Name

US-CATO

Product Number

C1359447

CAS

1643368-58-4

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

86582336

IUPAC Name

(7S)-3-fluoro-4-3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide

InChI Key

ZRYMMWAJAFUANM-INIZCTEOSA-N

SMILES

CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)CC@H(CC6)C(C)(C)O)C(=O)N)F

References Data Source From Pubchem

TTD: Therapeutic Target Database describing target druggability information

Publication Name: Nucleic Acids Research

Publication Date: 2023-09-15

DOI: 10.1093/nar/gkad751

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2021-11-04

DOI: 10.1021/acs.jmedchem.1c00926

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

Publication Name: Immunology

Publication Date: 2020-03-02

DOI: 10.1111/imm.13175

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Publication Name: Synfacts

Publication Date: 2018-08-20

DOI: 10.1055/s-0037-1610562

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

Publication Name: PLOS ONE

Publication Date: 2017-07-24

DOI: 10.1371/journal.pone.0181782

BMS-986142

Product Information

General Information

References Data Source From Pubchem

TTD: Therapeutic Target Database describing target druggability information

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

BMS-986142

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

BMS-986142

Product Information

General Information

References Data Source From Pubchem

TTD: Therapeutic Target Database describing target druggability information

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

BMS-986142

Related Product

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

#title#

Login

Register